IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.628
AS - Asia 1.055
EU - Europa 785
SA - Sud America 223
AF - Africa 23
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 3.724
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.569
SG - Singapore 490
IT - Italia 472
CN - Cina 243
BR - Brasile 169
DE - Germania 101
IN - India 97
VN - Vietnam 88
GB - Regno Unito 72
HK - Hong Kong 43
CA - Canada 38
SE - Svezia 35
FI - Finlandia 34
BD - Bangladesh 21
NL - Olanda 17
MX - Messico 14
ID - Indonesia 13
AR - Argentina 12
FR - Francia 11
ZA - Sudafrica 11
EC - Ecuador 10
JP - Giappone 9
RU - Federazione Russa 9
VE - Venezuela 8
ES - Italia 7
EU - Europa 7
AT - Austria 6
CO - Colombia 6
IQ - Iraq 6
PY - Paraguay 6
UZ - Uzbekistan 6
CL - Cile 5
KE - Kenya 5
PK - Pakistan 5
TR - Turchia 5
UA - Ucraina 5
CZ - Repubblica Ceca 4
JO - Giordania 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
LB - Libano 3
NP - Nepal 3
PE - Perù 3
AZ - Azerbaigian 2
ET - Etiopia 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
OM - Oman 2
PL - Polonia 2
SA - Arabia Saudita 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 3.724
Salva come PNG Salva come JPEG
Città #
San Jose 307
Singapore 216
Ashburn 169
Chandler 152
Dallas 79
Santa Clara 79
Munich 71
Bengaluru 66
Hefei 66
Beijing 54
Chicago 50
London 50
Catanzaro 46
Lawrence 44
Milan 44
Princeton 44
Hong Kong 40
Ho Chi Minh City 31
Naples 26
Hanoi 23
Turku 22
Los Angeles 19
Wilmington 18
Rome 17
New York 16
São Paulo 16
Parma 14
Des Moines 13
Ottawa 13
Brooklyn 12
Carbonia 12
Helsinki 12
Montreal 11
Boardman 9
Cosenza 8
Council Bluffs 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Aversa 7
Boston 6
Catania 6
Dhaka 6
Manchester 6
Melito di Porto Salvo 6
Reggio Calabria 6
Shanghai 6
Stockholm 6
Tashkent 6
Bologna 5
Charlotte 5
Chennai 5
Columbus 5
Guangzhou 5
Mexico City 5
Nairobi 5
Orem 5
Seattle 5
Settingiano 5
The Dalles 5
Amman 4
Brescia 4
Buffalo 4
Can Tho 4
Da Nang 4
Decollatura 4
Denver 4
Frankfurt am Main 4
Haiphong 4
Hanover 4
Jakarta 4
Jiaxing 4
Johannesburg 4
Mountain View 4
New Delhi 4
Phoenix 4
Pune 4
Redmond 4
Rio de Janeiro 4
San Francisco 4
Thái Bình 4
Tokyo 4
Acquaviva delle Fonti 3
Ahmedabad 3
Atlanta 3
Belo Horizonte 3
Berlin 3
Biên Hòa 3
Cape Town 3
Castrovillari 3
Guayaquil 3
Las Vegas 3
Madrid 3
Manaus 3
Mileto 3
Nova Iguaçu 3
Nuremberg 3
Olomouc 3
Totale 2.168
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 142
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 117
miR-22 suppresses DNA ligase III addiction in multiple myeloma 103
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 99
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 94
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 88
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 87
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 75
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 75
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 75
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 74
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 73
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 73
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 71
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 69
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 68
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 66
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 61
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 60
Mir-221/222 are promising targets for innovative anticancer therapy 60
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 58
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 58
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 57
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 57
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 57
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 55
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 53
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 52
Integration of DNA Microarray with Clinical and Genomic Data 52
Mmrf-commpass data integration and analysis for identifying prognostic markers 51
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 51
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 50
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 50
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 50
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 47
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 46
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 45
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 44
null 43
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 42
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 40
The potential role of miRNAs in multiple myeloma therapy 39
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 37
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 36
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 36
The potential role of miRNAs in multiple myeloma therapy 34
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 34
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 32
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 31
null 31
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 30
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 27
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 26
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 26
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 26
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 25
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 16
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 13
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 12
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager 9
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 9
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 5
PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma 4
Totale 3.863
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.718
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.718
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/20261.756 111 184 168 227 196 84 244 83 211 153 69 26
Totale 3.863